Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1962847 | 0.93 | KMT2A (0.49) | CHRNB2CHRNA4KMT2AKDM4EGAA | |
| SCHEMBL1965344 | 0.89 | RAB9A (0.53) | CHRNB2CHRNA4KMT2AKDM4EGAA | |
| SCHEMBL1780419 | 0.88 | CHRNB2 (0.56) | CHRNB2CHRNA4KMT2AKDM4EGAA | |
| SCHEMBL2976365 | 0.86 | MAPT (0.50) | KMT2ANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1963656 | 0.85 | CHRNB2 (0.53) | CHRNB2CHRNA4KMT2AKDM4EGAA | |
| SCHEMBL1962192 | 0.84 | CHRNB2 (0.59) | CHRNB2CHRNA4KMT2AKDM4EGAA | |
| SCHEMBL6377931 | 0.84 | KMT2A (0.57) | KMT2AGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1697621 | 0.84 | MAPT (0.67) | KMT2AGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2964413 | 0.83 | KMT2A (0.52) | KMT2AGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL657693 | 0.83 | CHEK1 (0.53) | KMT2AGAANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50082-E1 | (5,6-dihydro)pyrimido[4,5-e]indolizines | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2024-08-20 | — | — | US | disclosed |
| EP-3129374-B1 | (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES | NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) | 2018-12-19 | — | — | EP | disclosed |
| US-9856258-B2 | (5,6-dihydro)pyrimido[4,5-E]indolizines | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2018-01-02 | — | — | US | disclosed |
| US-20170096432-A1 | (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2017-04-06 | — | — | US | disclosed |
| EP-2961750-A1 | SUBSTITUTED 7-OXO-PYRIDO [2, 3-D]PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF EGFR / ERBB2 RELATED DISORDERS | Amgen Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| WO-2014134308-A1 | SUBSTITUTED 7-OXO-PYRIDO [2, 3-D] PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF EGFR / ERBB2 RELATED DISORDERS | AMGEN INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014134308-A1 | SUBSTITUTED 7-OXO-PYRIDO [2, 3-D] PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF EGFR / ERBB2 RELATED DISORDERS | AMGEN INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| EP-1919892-B1 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-1919892-B1 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2013-08-14 | — | — | EP | disclosed |
| US-8481568-B2 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481568-B2 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110144158-A1 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SEPRACOR INC. | 2011-06-16 | — | — | US | disclosed |
| US-20110144158-A1 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SEPRACOR INC. | 2011-06-16 | — | — | US | disclosed |
| US-20110144158-A1 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SEPRACOR INC. | 2011-06-16 | — | — | US | disclosed |
| EP-1919892-A2 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007027527-A2 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007027527-A2 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096432-A1 | (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES | DHFR, CYP2D6, DPYD | CHRNB2 4357/4885CHRNA4 3270/4885KMT2A 2106/4885 |
| US-20110144158-A1 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SI, CYP3A5, CYP2D6 | CHRNB2 3140/4885CHRNA4 3008/4885KMT2A 4292/4885 |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | SI, CYP3A5, CYP2D6 | CHRNB2 3140/4885CHRNA4 3008/4885KMT2A 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.